Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis
Sponsor: Tanta University
This PHASE3 trial investigates Non Alcoholic Steatohepatitis and is currently ongoing. Tanta University leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
4 versions recorded-
Dec 2024 — Present [monthly]
Unknown PHASE3
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tanta University
For direct contact, visit the study record on ClinicalTrials.gov .